A genetic risk factor for the development of #LongCovid!A new study identified the first genome-wide significant association for #LongCOVID at the FOXP4 locus. 1/
I kept looking for alternatives.
And wondered if it may be something else rare like these but it’s confusing and many include MRI imaging findings
Could mecfs lc somehow be in here too or not
COL4A2 was mentioned in a gene study relating to long Covid on here...
It is a rare genetic disorder of abnormal lymphocyte survival caused by defective Fasmediated apoptosis.<a href="https://en.wikipedia.org/wiki/Autoimmune_lymphoproliferative_syndrome#cite_note-pmid16522544-3"><span>[</span>3<span>]</span></a> Normally, after infectious insult, the immune system...
Excellent question — you’re now asking about transcription factors that regulate the expression of TLR7 itself (i.e., what turns the TLR7 gene on or off), rather than those activated downstream of TLR7 signaling.
Here’s a detailed overview:
Transcriptional Regulation of
TLR7
(Upstream...
Toll-like receptor 7 (TLR7) is a pattern recognition receptor that detects single-stranded RNA (ssRNA), often from viruses, and triggers downstream signaling pathways that induce innate immune responses — particularly type I interferon and proinflammatory cytokine production.
Here’s a breakdown...
https://studyfinds.org/blood-test-achieves-accuracy-diagnosing-chronic-fatigue-syndrome/
In A Nutshell
A 3D-DNA blood test (EpiSwitch CFS) identified ME/CFS with about 96% accuracy in a small validation study.
The strongest signals involve IL-2 and other immune-signaling pathways, hinting at...
Gpr52 links to schizophrenia as well
https://jpet.aspetjournals.org/article/S0022-3565(24)42361-6/abstract
GPR52 Constitutively Activates Multiple G Proteins and Beta-Arrestin2: Insights for Orphan GPCR Signaling (Abstract ID: 167613)
Jones Addiah-Nickson ∙ Ryan E. Murphy ∙ John A. Allen...
https://www.diabetes.co.uk/news/2025/aug/sglt-2-inhibitors-to-become-first-choice-treatments-for-type-2-diabetes.html
Draft NICE guidelines propose upgrading Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors from second choice to first-choice treatments for type 2 diabetes.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.